Insulet (PODD)
(Delayed Data from NSDQ)
$191.54 USD
-3.05 (-1.57%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $191.60 +0.06 (0.03%) 5:00 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Brokerage Reports
Insulet Corporation [PODD]
Reports for Purchase
Showing records 141 - 160 ( 344 total )
Company: Insulet Corporation
Industry: Medical - Products
Insulet''s 1Q Results Stands out Among its Diabetes Peers; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Discontinuation of Research Coverage
Provider: Feltl & Company
Company: Insulet Corporation
Industry: Medical - Products
Onpro Kit Exits 1Q17 with 50% Share of Amgen''s Neulasta Franchise and Continues to Grow
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Prescription Tracker (March): Share of Onpro Recovers; Now For the First Time Represents Over 50% of Neulasta Franchise
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
1Q17 Preview: Outperforming in MedTech Year-to-Date Reflects Stable Fundamentals That Should Continue Throughout 2017
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Prescription Tracker (February): Share of Onpro Slips Slightly in February
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Revenue strong in Q4, guidance inline with expectations - maintain HOLD, $41.50PT
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
PODD Delivers a Solid Quarter and Issues Healthy Outlook; Reiterate OUTPERFORM and Raising PT to $50
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Prescription Tracker (January): Normalizing for the Expected Semi-Annual Spike in Neulasta Scripts, Share of Onpro at Over 50%
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Update on Neulasta Onpro Kit From Amgen''s EPS Call; Share of Neulasta Franchise Expected To Continue Growing
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Medical Devices: Diabetes Market Implications from JNJ''s Potential Exit
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
CMS to Reimburse DXCM''s G5; Positive for DXCM, PODD, TNDM; Negative for MDT
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Prescription Tracker (November): Latest RX Data Continue To Point Toward 50% Share of Neulasta by Yearend; Reit. OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Monthly Neulasta Onpro Prescription Tracker: October Results In Line; On Track For 50% Share of Neulasta by Yearend; Reit. OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Analyst Day Highlights a Solid Foundation From Which to Drive Robust Growth; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Another "beat-and-raise", strength across the board - reiterate BUY, target to $41.50
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
3Q16 Results - A Ray of Sunshine in an Otherwise Gloomy Diabetes Quarter; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Company: Insulet Corporation
Industry: Medical - Products
Amgen''s Reported Onpro Kit Share In Line with Our Analysis and On Track to Capture 50% of Neulasta Franchise Exiting 2016; Maintain OUTPERFORM
Provider: WEDBUSH SECURITIES INC.